Clinical characteristics of participants
Clinical characteristics . | No. . |
---|---|
N | 34 |
Age, median (range), y | 56 (22-73) |
Sex, M/F | 21/13 |
Diagnosis, no. | |
AML | 7 |
ALL | 7 |
MDS | 7 |
NHL | 5 |
MPN | 3 |
Multiple myeloma | 2 |
Other* | 3 |
Donor | |
Matched unrelated | 18 |
Matched related | 7 |
Mismatched unrelated | 5 |
Umbilical cord blood | 4 |
Stem cell source | |
Peripheral blood stem cells | 29 |
Bone marrow | 1 |
Umbilical cord blood | 4 |
Conditioning regimen | |
Myeloablative | 11 |
Reduced intensity | 23 |
GVHD prophylaxis | |
Tacrolimus/MTX | 17 |
Tacrolimus/sirolimus ± MTX | 3 |
Tacrolimus/MTX/other† | 7 |
Tacrolimus or cyclosporine/MMF | 5 |
Ex vivo T-cell depletion | 2 |
aGVHD grade at enrollment | |
II | 10 |
III | 22 |
IV | 8 |
Time from aGVHD onset to day 1 of BV, median (range) | 31 d (6-185) |
Time from day 0 of HCT (or DLI) to day 1 of BV, median (range) | 88 d (28-371) |
Category of SR-aGVHD | |
Progressing or not improving on initial steroids | 25 |
Flare upon steroid tapering | 9 |
BV dose level | |
0.6 mg/kg IV weekly × 3 | 3 |
0.9 mg/kg IV weekly × 3 | 3 |
0.6 mg/kg IV every other week × 4 | 10 |
0.8 mg/kg IV every other week × 4 | 18 |
Clinical characteristics . | No. . |
---|---|
N | 34 |
Age, median (range), y | 56 (22-73) |
Sex, M/F | 21/13 |
Diagnosis, no. | |
AML | 7 |
ALL | 7 |
MDS | 7 |
NHL | 5 |
MPN | 3 |
Multiple myeloma | 2 |
Other* | 3 |
Donor | |
Matched unrelated | 18 |
Matched related | 7 |
Mismatched unrelated | 5 |
Umbilical cord blood | 4 |
Stem cell source | |
Peripheral blood stem cells | 29 |
Bone marrow | 1 |
Umbilical cord blood | 4 |
Conditioning regimen | |
Myeloablative | 11 |
Reduced intensity | 23 |
GVHD prophylaxis | |
Tacrolimus/MTX | 17 |
Tacrolimus/sirolimus ± MTX | 3 |
Tacrolimus/MTX/other† | 7 |
Tacrolimus or cyclosporine/MMF | 5 |
Ex vivo T-cell depletion | 2 |
aGVHD grade at enrollment | |
II | 10 |
III | 22 |
IV | 8 |
Time from aGVHD onset to day 1 of BV, median (range) | 31 d (6-185) |
Time from day 0 of HCT (or DLI) to day 1 of BV, median (range) | 88 d (28-371) |
Category of SR-aGVHD | |
Progressing or not improving on initial steroids | 25 |
Flare upon steroid tapering | 9 |
BV dose level | |
0.6 mg/kg IV weekly × 3 | 3 |
0.9 mg/kg IV weekly × 3 | 3 |
0.6 mg/kg IV every other week × 4 | 10 |
0.8 mg/kg IV every other week × 4 | 18 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; DLI, donor leukocyte infusion; F, female; M, male; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MPN, myeloproliferative neoplasm; MTX, methotrexate; NHL, non-Hodgkin lymphoma.
Other diagnoses: aplastic anemia, blastic plasmacytoid dendritic cell neoplasm, chronic myelomonocytic leukemia.
Other GVHD prophylaxis: 3, ATG; 1, ATG or placebo; 1, bortezomib; 1, Milatuzumab; 1, RGI-2001.